Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Business
STAT+

Novartis CEO Vas Narasimhan on gene therapy, innovation, and the company pivot

By Karen WeintraubOct. 29, 2018

Reprints
Vasant "Vas" Narasimhan
Novartis CEO Vas Narasimhan Alissa Ambrose/STAT

When the drug maker Novartis announced last month that it would cut 2,200 jobs, it framed the decision not as a retreat but as a restructuring. The goal, CEO Vas Narasimhan said, was to reshape the company to focus on “specialized and more personalized innovative medicines.”

Out with the company’s contact lens business, in with cancer immunotherapy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Karen Weintraub

Karen Weintraub is an independent health/science journalist, journalism teacher, and book author.

Tags

Watch: P-value, an important measurement in clinical trials, explained
Watch: P-value, an important measurement in clinical trials, explained
‘What could help me to die?’ Doctors clash over…
‘What could help me to die?’ Doctors clash over euthanasia
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Study finds same small rise in breast cancer risk…
Study finds same small rise in breast cancer risk in many forms of hormonal birth control
Patient groups balk at former AstraZeneca official negotiating U.K.-India…
Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal
Altimmune’s obesity drug fails to stand out from blockbuster…
Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data

Recommended Stories